{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:25Z","timestamp":1786980145933,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012643","name":"Ohio Lions Eye Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012643","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["K08EY022672"],"award-info":[{"award-number":["K08EY022672"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Patti Blow Fund"},{"name":"Retina Research in Ophthalmology","award":["313310"],"award-info":[{"award-number":["313310"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00417-019-04337-8","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T04:09:33Z","timestamp":1557979773000},"page":"1771-1781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics"],"prefix":"10.1007","volume":"257","author":[{"given":"Anne L.","family":"Kunkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimosthenis","family":"Mantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Hendershot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Ohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari L.","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick H.","family":"Davidorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Cebulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"issue":"21","key":"4337_CR1","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita","year":"2008","unstructured":"DeVita VT, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68(21):8643\u20138653","journal-title":"Cancer Res"},{"issue":"1","key":"4337_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.survophthal.2005.11.001","volume":"51","author":"KE Schmid","year":"2006","unstructured":"Schmid KE, Kornek GV, Scheithauer W, Binder S (2006) Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 51(1):19\u201340","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"4337_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/IAE.0000000000000242","volume":"34","author":"CY Liu","year":"2014","unstructured":"Liu CY, Francis JH, Brodie SE, Marr B, Pulido JS, Marmor MF et al (2014) Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 34(7):1261\u20131280","journal-title":"Retina"},{"issue":"3","key":"4337_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","volume":"50","author":"O Huillard","year":"2014","unstructured":"Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S et al (2014) Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer 50(3):638\u2013648","journal-title":"Eur J Cancer"},{"issue":"7","key":"4337_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","volume":"91","author":"WL Ho","year":"2013","unstructured":"Ho WL, Wong H, Yau T (2013) The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 91(7):604\u2013609","journal-title":"Acta Ophthalmol"},{"key":"4337_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/OTT.S54606","volume":"7","author":"T Hager","year":"2013","unstructured":"Hager T, Seitz B (2013) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 7:69\u201377","journal-title":"Onco Targets Ther"},{"issue":"26","key":"4337_CR7","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","volume":"30","author":"DJ Renouf","year":"2012","unstructured":"Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL (2012) Ocular toxicity of targeted therapies. J Clin Oncol 30(26):3277\u20133286","journal-title":"J Clin Oncol"},{"issue":"35","key":"4337_CR8","doi-asserted-by":"crossref","first-page":"58709","DOI":"10.18632\/oncotarget.17634","volume":"8","author":"C Fu","year":"2017","unstructured":"Fu C, Gombos DS, Lee J et al (2017) Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget 8(35):58709\u201358727","journal-title":"Oncotarget"},{"issue":"8","key":"4337_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","volume":"133","author":"D Mantopoulos","year":"2015","unstructured":"Mantopoulos D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133(8):965\u2013967","journal-title":"JAMA Ophthalmol"},{"key":"4337_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2415-13-42","volume":"13","author":"LD Turner","year":"2013","unstructured":"Turner LD, Harrison JD (2013) Bilateral optic disc edema and associated optic neuropathy in the setting of FOLFOX chemotherapy. BMC Ophthalmol 13:42","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"4337_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1200\/JCO.1985.3.12.1683","volume":"3","author":"G Wilding","year":"1985","unstructured":"Wilding G, Caruso R, Lawrence TS et al (1985) Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 3(12):1683\u20131689","journal-title":"J Clin Oncol"},{"key":"4337_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF01203656","volume":"84","author":"MF Marmor","year":"1993","unstructured":"Marmor MF (1993) Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 84:237\u2013246","journal-title":"Doc Ophthalmol"},{"key":"4337_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1634\/theoncologist.2011-0324","volume":"17","author":"JG Monzon","year":"2012","unstructured":"Monzon JG, Hammad N, Stevens SD, Dancey J (2012) Retinopathy associated with adjuvant high-dose interferon-a2b in a patient with resected melanoma: a case report and review of the literature. Oncologist 17:384\u2013387","journal-title":"Oncologist"},{"issue":"2","key":"4337_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0404.2011.01532.x","volume":"125","author":"F Patti","year":"2012","unstructured":"Patti F, Nicoletti A, Pappalardo A, Castiglione A, Lo Fermo S, Messina S et al (2012) Frequency and severity of headache is worsened by interferon-\u03b2 therapy in patients with multiple sclerosis. Acta Neurol Scand 125(2):91\u201395","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"4337_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib verses ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213\u2013223","journal-title":"N Engl J Med"},{"issue":"18","key":"4337_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang Y-J, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693\u20131703","journal-title":"N Engl J Med"},{"issue":"5","key":"4337_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.ajo.2015.07.035","volume":"160","author":"A Niro","year":"2015","unstructured":"Niro A, Strippoli S, Alessio G et al (2015) Ocular toxicity in metastatic melanoma patients treated with mitogen-activated protein kinase inhibitors: a case series. Am J Ophthalmol 160(5):959\u2013967.e1","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"4337_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM et al (2017) Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124(12):1788\u20131798","journal-title":"Ophthalmology"},{"issue":"8","key":"4337_CR19","doi-asserted-by":"publisher","first-page":"e0135521","DOI":"10.1371\/journal.pone.0135521","volume":"10","author":"T Ishii","year":"2015","unstructured":"Ishii T, Iwasawa S, Kurimoto R, Maeda A, Takiguchi Y, Kaneda M (2015) Crizotinib-induced abnormal signal processing in the retina. PLoS One 10(8):e0135521","journal-title":"PLoS One"},{"key":"4337_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00006324-199705000-00025","volume":"74","author":"S Hickson","year":"1997","unstructured":"Hickson S, Papas E (1997) Prevalence of idiopathic corneal anomalies in a non contact lens-wearing population. Optom Vis Sci 74:293\u2013297","journal-title":"Optom Vis Sci"},{"issue":"12","key":"4337_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/bjo.64.12.888","volume":"64","author":"JA Humphreys","year":"1980","unstructured":"Humphreys JA, Larke JR, Parrish ST (1980) Microepithelial cysts observed in extended contact-lens wearing subjects. Br J Ophthalmol 64(12):888\u2013889","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"4337_CR22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","volume":"35","author":"KN Moore","year":"2017","unstructured":"Moore KN, Martin LP, O\u2019Malley DM et al (2017) Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol 35(10):1112\u20131118","journal-title":"J Clin Oncol"},{"issue":"5","key":"4337_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3109\/02713683.2011.566411","volume":"36","author":"J Jwaka","year":"2011","unstructured":"Jwaka J, Boddu S, Paturi DK, Shah S, Smith SB, Pal D, Mitra AK (2011) Functional characterization of folate transport proteins in Staten\u2019s seruminstitut rabbit corneal epithelial cell line. Curr Eye Res 36(5):404\u2013416","journal-title":"Curr Eye Res"},{"issue":"10","key":"4337_CR24","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ (2015) Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther 31(10):589\u2013604","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-019-04337-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-019-04337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T09:11:18Z","timestamp":1589620278000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-019-04337-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["4337"],"URL":"https:\/\/doi.org\/10.1007\/s00417-019-04337-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"27 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anne Kunkler declares that she has no conflict of interest. Elaine M. Binkley declares that she has no conflict of interest. Dimosthenis Mantopoulos declares that he has no conflict of interest. Andrew J. Hendershot declares that he has no conflict of interest. Matthew P. Ohr declares that he has no conflict of interest. Kari L. Kendra declares that she has no conflict of interest. Frederick H. Davidorf declares that he has no conflict of interest. Colleen M. Cebulla declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All research activities were in accordance with the ethical standards of the institutional review board committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The retrospective review was approved by the institutional review board committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}